Novacea, Inc.
|
601 Gateway Blvd., Suite 800
South San Francisco, CA 94080
USA
United States |
| Tel: |
1/650 228-1088 |
| URL: |
http://www.novacea.com |
|
| Formerly known as: |
| D-Novo Therapeutics, Inc. |
 |
| Primary Symbols & Exchanges: |
| NOVC - NASDAQ |
| - Berlin-Bremen Stock Exchange |
|
|
| Primary Industry: |
| Biotechnology |
|
|
SIC Industry Code:
|
|
NAICS Industry Code:
|
|
Thomson Financial Business Description:
| The Group's principal activity is that of a biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for the treatment of cancer. Its product portfolio features three clinical-stage oncology product candidates: DN-101, vinorelbine oral and AQ4N. Its lead product candidate, DN-101, is in a Phase 3 clinical trial for the treatment of androgen-independent prostate cancer. AQ4N is expected to advance into a Phase 1/2 clinical trial in the second half of 2006 for glioblastoma multiforme in combination with radiation and chemotherapy. It also seeks to develop anti-cancer agents that may reduce the toxicities associated with current treatments. Trademarks include Asentar and We Can. In May 2007, the Group signed an exclusive License, Development and Commercialization Agreement with Schering Corporation for the development and commercialization of 'Asentar.' |
|
Alacra Alerts:
 
|
Receive alerts on the latest reports on Novacea, Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
|
|
